A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVE: This debate paper aims to examine the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), whose use in obesity and diabetes management has rapidly expanded, on fertility, contraceptive efficacy, and pregnancy outcomes in repr…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for the management of obesity and type 2 diabetes, particularly among women of reproductive age. Emerging evidence suggests potential effects on ovulation, fertility, and preg…
INTRODUCTION: Obesity is a global public health issue, with its effects a particular issue in Kuwait. Advances in pharmaceutical treatment (eg, glucagon-like peptide-1s) offer an effective solution, with the magnitude of weight lost something to cele…
AIMS: Tirzepatide, an injectable glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP-1 RAs, such as semaglutide, are under invest…
OBJECTIVES: We reviewed weight loss and gaining wrinkles, and the impact of weight loss drugs on facial aesthetics. METHODS: The resources from Eskişehir Osmangazi and Kirikkale Universities, along with Google, Google Scholar, PubMed, EBSCO, and ProQ…
OBJECTIVES: To evaluate the quality, reliability, and thematic content of user-generated videos on TikTok concerning glucagon-like peptide-1 (GLP-1) receptor agonists. METHODS: This cross-sectional study analyzed the top 400 most popular videos using…
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved to treat obstructive sleep apnea (OSA), yet their use in an OSA population has not been characterized. This study evaluates GLP-1 RA use in patients presenting to a sleep s…
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, exhibits significant neuroprotective effects in stroke and neurodegenerative diseases. However, the antiinflammatory and barrier-protective effects of semaglutide and the mechanisms…
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver-related morbidity driven by systemic metabolic dysregulation. The recent approval of resmetirom and the clinical success of GLP-1 receptor agonists have heralded a ne…
BACKGROUND: While the FLOW trial established the renoprotective effects of subcutaneous semaglutide, real-world evidence regarding the long-term renal effects of therapeutic switching from injectable glucagon-like peptide-1 receptor agonists (GLP-1RA…
The intricate interplay of physiological, psychological, and social factors presents considerable challenges in addressing heart failure. It is imperative to comprehend the epidemiology and pathophysiology, identify predictors and their influence on…
INTRODUCTION: Tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP1RA) and glucose-dependent insulinotropic-peptide (GIP), has shown efficacy regarding weight-loss. METHODS: Systematic review and network meta-analysis of randomized controlled…
Pediatric obesity is a common chronic disease with serious long-term health consequences. This narrative review compares current international and national recommendations for the diagnosis and management of pediatric obesity. We focus on guidance fr…
BACKGROUND: Brachial plexus neuritis, or Parsonage–Turner syndrome, is an uncommon neuropathy marked by acute pain followed by weakness, often triggered by infection, vaccination, trauma, or metabolic stress but the exact cause of this disease remain…
BACKGROUND: Effective weight management and glycemic control are both important in people with type 2 diabetes (T2D) and obesity. Despite the proven benefits of GLP-1 receptor agonists, there is a persistent need for more effective weight management…
Semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has attracted significant global attention for its appetite-suppressing and weight-loss effects. Approved for pediatric use in child…
AIMS: Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model-informed drug development (MIDD) to evaluate whether a 1.7-mg maintenance dose provides comparab…